{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:51:47Z","timestamp":1724295107783},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Urovant Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40801-023-00370-6","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T09:02:39Z","timestamp":1684832559000},"page":"439-446","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder"],"prefix":"10.1007","volume":"10","author":[{"given":"Jingjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamika","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Carbonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Goti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia J.","family":"Girman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"370_CR1","doi-asserted-by":"crossref","unstructured":"Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline: American Urological Association, 2019.","DOI":"10.1097\/JU.0000000000000309"},{"issue":"6","key":"370_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336. https:\/\/doi.org\/10.1007\/s00345-002-0301-4.","journal-title":"World J Urol"},{"issue":"4","key":"370_CR3","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","volume":"109","author":"CV Asche","year":"2012","unstructured":"Asche CV, Kim J, Kulkarni AS, Chakravarti P, Andersson KE. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting. BJU Int. 2012;109(4):572\u201380. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10436.x.","journal-title":"BJU Int"},{"issue":"12","key":"370_CR4","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","volume":"32","author":"ML Ganz","year":"2016","unstructured":"Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997\u20132005. https:\/\/doi.org\/10.1080\/03007995.2016.1226167.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"370_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1055\/s-0042-114221","volume":"76","author":"CS Schneidinger","year":"2016","unstructured":"Schneidinger CS, Umek W, Bohmdorfer B. The problem of polypharmacy in female patients with overactive bladders - cross-sectional study in a specialist outpatient department. Geburtshilfe Frauenheilkd. 2016;76(12):1318\u201324. https:\/\/doi.org\/10.1055\/s-0042-114221.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"4","key":"370_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"370_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28\u201337. https:\/\/doi.org\/10.1002\/nau.24536.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"370_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ageing\/afu096","volume":"43","author":"C Fox","year":"2014","unstructured":"Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604\u201315. https:\/\/doi.org\/10.1093\/ageing\/afu096.","journal-title":"Age Ageing"},{"issue":"11","key":"370_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40266-020-00792-9","volume":"37","author":"G Lozano-Ortega","year":"2020","unstructured":"Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, et al. Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis. Drugs Aging. 2020;37(11):801\u201316. https:\/\/doi.org\/10.1007\/s40266-020-00792-9.","journal-title":"Drugs Aging"},{"key":"370_CR10","volume-title":"MYRBETRIQ\u00ae(mirabegron extended-release tablets)","author":"Astellas Pharma US Inc.","year":"2018","unstructured":"Astellas Pharma US Inc. MYRBETRIQ\u00ae (mirabegron extended-release tablets). Full Prescribing Information: Astellas Pharma US Inc; 2018."},{"key":"370_CR11","unstructured":"US Food and Drug Administration. Clinical drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. Silver Spring, MD: US Food and Drug Administration, 2020."},{"issue":"1","key":"370_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13318-013-0133-1","volume":"39","author":"W Krauwinkel","year":"2014","unstructured":"Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, et al. The effect of mirabegron, a potent and selective \u03b23-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43\u201352. https:\/\/doi.org\/10.1007\/s13318-013-0133-1.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"370_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist. Xenobiotica. 2012;42(12):1187\u201396. https:\/\/doi.org\/10.3109\/00498254.2012.700140.","journal-title":"Xenobiotica"},{"issue":"1","key":"370_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6\u201313. https:\/\/doi.org\/10.1038\/sj.tpj.6500285.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"370_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40801-022-00339-x","volume":"10","author":"ME Ritchey","year":"2023","unstructured":"Ritchey ME, Wang J, Young JC, Chandra R, Carrera A, Goti N, et al. CYP2D6 substrate dispensing among patients dispensed mirabegron: an administrative claims analysis. Drugs Real World Outcomes. 2023;10(1):119\u201329. https:\/\/doi.org\/10.1007\/s40801-022-00339-x.","journal-title":"Drugs Real World Outcomes."},{"issue":"4","key":"370_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40261-021-01020-x","volume":"41","author":"MP Rutman","year":"2021","unstructured":"Rutman MP, Horn JR, Newman DK, Stefanacci RG. Overactive bladder prescribing considerations: the role of polypharmacy, anticholinergic burden, and CYP2D6 drug-drug interactions. Clin Drug Investig. 2021;41(4):293\u2013302. https:\/\/doi.org\/10.1007\/s40261-021-01020-x.","journal-title":"Clin Drug Investig"},{"key":"370_CR17","doi-asserted-by":"publisher","unstructured":"Stefanacci RG, Horn JR, Yeaw J, Shah D, Carrera A, Goti N, et al. High utilization of CYP2D6 substrate prescriptions among long-term care residents with overactive bladder. Ann Long-Term Care. 2022;2:1\u20138. https:\/\/doi.org\/10.25270\/altc.2022.10.001.","DOI":"10.25270\/altc.2022.10.001"},{"issue":"12","key":"370_CR18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40266-021-00901-2","volume":"38","author":"NL Campbell","year":"2021","unstructured":"Campbell NL, Hines L, Epstein AJ, Walker D, Lockefeer A, Shiozawa A. A 12-year retrospective study of the prevalence of anticholinergic polypharmacy and associated outcomes among Medicare patients with overactive bladder in the USA. Drugs Aging. 2021;38(12):1075\u201385. https:\/\/doi.org\/10.1007\/s40266-021-00901-2.","journal-title":"Drugs Aging"},{"issue":"1","key":"370_CR19","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1038\/s41598-021-85022-x","volume":"11","author":"ML Dahl","year":"2021","unstructured":"Dahl ML, Leander K, Vikstrom M, Frumerie C, Nordenmalm S, Moller J, et al. CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study. Sci Rep. 2021;11(1):5796. https:\/\/doi.org\/10.1038\/s41598-021-85022-x.","journal-title":"Sci Rep"},{"issue":"8","key":"370_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/acem.12431","volume":"21","author":"AA Monte","year":"2014","unstructured":"Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug\u2013drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014;21(8):879\u201385. https:\/\/doi.org\/10.1111\/acem.12431.","journal-title":"Acad Emerg Med."},{"issue":"6","key":"370_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.dmpk.2016.08.002","volume":"31","author":"Y Nomura","year":"2016","unstructured":"Nomura Y, Iitsuka H, Toyoshima J, Kuroishi K, Hatta T, Kaibara A, et al. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug Metab Pharmacokinet. 2016;31(6):411\u20136. https:\/\/doi.org\/10.1016\/j.dmpk.2016.08.002.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"370_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jamia\/ocx115","volume":"25","author":"KC Nanji","year":"2018","unstructured":"Nanji KC, Seger DL, Slight SP, Amato MG, Beeler PE, Her QL, et al. Medication-related clinical decision support alert overrides in inpatients. J Am Med Inform Assoc. 2018;25(5):476\u201381. https:\/\/doi.org\/10.1093\/jamia\/ocx115.","journal-title":"J Am Med Inform Assoc"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00370-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00370-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00370-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:12:24Z","timestamp":1694193144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00370-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["370"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00370-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"16 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MER, JW, AC, and CJG developed the protocol. JW and MC analyzed the data. All authors contributed to the interpretation of data, revised the manuscript for intellectual content, and read and approved the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}},{"value":"Funding for this analysis and for medical writing and editorial assistance was provided by Urovant Sciences (Irvine, CA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JW is an employee of Sumitovant Biopharma, Inc. MER was a consultant for CERobs Consulting, LLC, a consulting firm that was contracted by Urovant Sciences and consults with other pharmaceutical companies, at the time the work was conducted. KR was an employee of CERobs Consulting, LLC, at the time the work was conducted. MC was an employee of Roivant Sciences, Inc., and a consultant to Sumitovant Biopharma, Inc., at the time the work was conducted. AC is an employee of Urovant Sciences and Duke Health. NG is an employee of Urovant Sciences. JRH is a coauthor and publisher of <i>The Top 100 Drug Interactions: A Guide to Patient Management<\/i> and a consultant to Urovant Sciences and Seegnal US. CJG is the President of CERobs Consulting, LLC, a consulting firm that consults with pharmaceutical companies and was contracted by Urovant Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Datasets generated and\/or analyzed during the current study are available from Sumitovant Biopharma, Inc (Jingjun Wang; monica.wang@sumitovant.com), through licensing with IQVIA, Inc, and requests will be considered from qualified researchers on a case-by-case basis with the condition of IQVIA approval.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This retrospective database analysis used deidentified claims data from the IQVIA PharMetrics<sup>\u00ae<\/sup> Plus database, which is compliant with the Health Insurance Portability and Accountability Act to protect patient privacy.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}